275 related articles for article (PubMed ID: 33273263)
1. Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases.
Santoro RC; Falbo M; Levato L; Iannaccaro P; Prejanò S
Blood Coagul Fibrinolysis; 2021 Mar; 32(2):159-161. PubMed ID: 33273263
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
3. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
5. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
Wimalachandra M; Basu TN; Salisbury J; Attard N; Calonje E; Patten PEM
Clin Exp Dermatol; 2021 Dec; 46(8):1569-1571. PubMed ID: 34028865
[No Abstract] [Full Text] [Related]
7. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
[TBL] [Abstract][Full Text] [Related]
8. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
9. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Dong R; Yan Y; Zeng X; Lin N; Tan B
Drug Des Devel Ther; 2022; 16():3225-3239. PubMed ID: 36164415
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
12. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
13. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Stühlinger MC; Weltermann A; Staber P; Heintel D; Nösslinger T; Steurer M
Wien Klin Wochenschr; 2020 Feb; 132(3-4):97-109. PubMed ID: 31414181
[TBL] [Abstract][Full Text] [Related]
16. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
18. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
